Protein kinase C inhibitors and uses thereof
View Patent ↗This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
1. A compound of the formula (I):
wherein
R 5 is selected from haloalkyl, alkoxy, substituted alkoxy, cyano, halogen, acyl, aminoacyl, and nitro;
Y 1 and Y 2 are independently selected from hydrogen, alkyl, and acyl;
R 1 is selected from hydrogen, alkyl, and substituted alkyl;
R a and R b are independently selected from hydrogen and alkyl;
R c and R d are independently selected from hydrogen and alkyl;
R 6a is selected from hydrogen, alkyl, substituted alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;
R 6b is fluoro;
R 7b is selected from hydrogen, alkyl, substituted alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;
R 8 is selected from hydrogen, C 2-10 alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;
R 7x is selected from hydrogen, alkyl, haloalkyl, cycloalkyl, and substituted cycloalkyl; and
wherein if R 8 is fluoro, then R 7b is not hydrogen;
or a salt or stereoisomer thereof.
2. The compound of claim 1 , wherein the compound is of the formula (II):
wherein
R 5 is selected from haloalkyl, alkoxy, substituted alkoxy, cyano, halogen, acyl, aminoacyl, and nitro;
Y 1 and Y 2 are independently selected from hydrogen, alkyl, and acyl;
R 1 is selected from hydrogen, alkyl, and substituted alkyl;
R a and R b are independently selected from hydrogen and alkyl;
R c and R d are independently selected from hydrogen and alkyl;
R 6a is selected from hydrogen, alkyl, substituted alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;
R 6b is fluoro;
R 7b is selected from hydrogen, alkyl, substituted alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;
R 8 is selected from hydrogen, C 2-10 alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl; and
R 7x is selected from hydrogen, alkyl, haloalkyl, cycloalkyl, and substituted cycloalkyl;
or a salt or stereoisomer thereof.
3. The compound of claim 1 , wherein the compound is of the formula (III):
wherein
R 5 is selected from haloalkyl, alkoxy, substituted alkoxy, cyano, halogen, acyl, aminoacyl, and nitro;
Y 1 and Y 2 are independently selected from hydrogen, alkyl, and acyl;
R 1 is selected from hydrogen, alkyl, and substituted alkyl;
R a and R b are independently selected from hydrogen and alkyl;
R c and R d are independently selected from hydrogen and alkyl;
R 6a is selected from hydrogen, alkyl, substituted alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;
R 6b is fluoro;
R 7b is selected from hydrogen, alkyl, substituted alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;
R 8 is selected from hydrogen, C 2-10 alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;
R 7x is selected from hydrogen, alkyl, haloalkyl, cycloalkyl, and substituted cycloalkyl; and
wherein at least one of R 6a , R 6b , R 7b , and R 8 is cycloalkyl, alkyl, or C 2-10 alkyl;
or a salt or stereoisomer thereof.
4. The compound of claim 1 , wherein the compound is of the formula (IV):
wherein
R 5 is selected from haloalkyl, alkoxy, substituted alkoxy, cyano, halogen, acyl, aminoacyl, and nitro;
Y 1 and Y 2 are independently selected from hydrogen, alkyl, and acyl;
R 1 is selected from hydrogen, alkyl, and substituted alkyl;
R a and R b are independently selected from hydrogen and alkyl;
R c and R d are independently selected from hydrogen and alkyl;
R 6a is selected from hydrogen, alkyl, substituted alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;
R 6b is fluoro;
R 7b is selected from hydrogen, alkyl, substituted alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;
R 8 is selected from hydrogen, C 2-10 alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;
R 7x is selected from hydrogen, alkyl, haloalkyl, cycloalkyl, and substituted cycloalkyl; and
wherein at least one of R 6a , R 6b , R 7b , and R 8 is C 2-10 alkyl;
or a salt or stereoisomer thereof.
5. The compound of claim 1 , wherein the compound is of the formula (V):
wherein
R 5 is selected from haloalkyl, alkoxy, substituted alkoxy, cyano, halogen, acyl, aminoacyl, and nitro;
Y 1 and Y 2 are independently selected from hydrogen, alkyl, and acyl;
R 1 is selected from hydrogen, alkyl, and substituted alkyl;
R a and R b are independently selected from hydrogen and alkyl;
R c and R d are independently selected from hydrogen and alkyl;
R 6a is selected from hydrogen, alkyl, substituted alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;
R 6b is fluoro;
R 7b is selected from hydrogen, alkyl, substituted alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl;
R 8 is selected from hydrogen, C 2-10 alkyl, cyano, halogen, acyl, aminoacyl, nitro, cycloalkyl, and substituted cycloalkyl; and
R 7x is haloalkyl;
or a salt or stereoisomer thereof.
6. The compound of claim 1 , wherein R 5 is cyano, halogen, acyl, or aminoacyl.
7. The compound of claim 1 , wherein Y 1 is hydrogen and Y 2 is hydrogen.
8. The compound of claim 1 , wherein R 1 is hydrogen.
9. The compound of claim 1 , wherein R a and R b are both alkyl and R c and R d are both alkyl.
10. The compound of claim 1 , wherein at least one of R 6a , R 6b , R 7b , and R 8 is selected from C 2-10 alkyl, halogen, and cycloalkyl.
11. The compound of claim 1 , wherein R 6a is hydrogen.
12. The compound of claim 1 , wherein R 8 is cyclopropyl or substituted cyclopropyl.
13. The compound of claim 1 , wherein R 7x is hydrogen.
14. The compound of claim 1 , wherein R 7x is trifluoromethyl or fluoromethyl.
15. The compound of claim 1 , wherein R 7x is alkyl or cycloalkyl.
16. A compound selected from
I-1: N2-(4-Cyclopropyl-2-fluoro-5-tetrazol-1-yl-phenyl)-5-fluoro-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;
I-2: 2-(4-Cyclopropyl-2-fluoro-5-tetrazol-1-yl-phenylamino)-4-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidine-5-carbonitrile;
I-3: 2-(4-Cyclopropyl-2-fluoro-5-tetrazol-1-yl-phenylamino)-4-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidine-5-carboxylic acid amide;
I-4: 2-(4-Cyclopropyl-3-fluoro-5-tetrazol-1-yl-phenylamino)-4-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidine-5-carbonitrile;
I-5: N2-(4-Cyclopropyl-3-fluoro-5-tetrazol-1-yl-phenyl)-5-fluoro-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;
I-6: 2-(3-Cyclopropyl-4-fluoro-5-tetrazol-1-yl-phenylamino)-4-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidine-5-carbonitrile;
I-7: N2-(3-Cyclopropyl-4-fluoro-5-tetrazol-1-yl-phenyl)-5-fluoro-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;
I-8: 2-(2-Fluoro-4-isopropyl-5-tetrazol-1-yl-phenylamino)-4-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidine-5-carbonitrile;
I-9: 5-Fluoro-N2-(4-isopropyl-3-tetrazol-1-yl-phenyl)-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;
I-10: 2-(4-Isopropyl-3-tetrazol-1-yl-phenylamino)-4-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidine-5-carboxylic acid amide;
I-11: 2-(4-Isopropyl-3-tetrazol-1-yl-phenylamino)-4-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidine-5-carbonitrile;
I-13: 5-Fluoro-N2-(2-fluoro-5-tetrazol-1-yl-phenyl)-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;
I-14: 5-Fluoro-N2-(2-fluoro-5-tetrazol-1-yl-phenyl)-N4-(1,2,2,6,6-pentamethyl-piperidin-4-yl)-pyrimidine-2,4-diamine; and
I-15: N2-[4-Cyclopropyl-3-(5-trifluoromethyl-tetrazol-1-yl)-phenyl]-5-fluoro-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine;
I-16: N2-(4-cyclopropyl-2-fluoro-5-(5-isopropyl-1H-tetrazol-1-yl)phenyl)-5-fluoro-N4-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine;
I-17: N2-(4-cyclopropyl-5-(5-cyclopropyl-1H-tetrazol-1-yl)-2-fluorophenyl)-5-fluoro-N4-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine;
I-18: N2-(4-cyclopropyl-2-fluoro-5-(5-methyl-1H-tetrazol-1-yl)phenyl)-5-fluoro-N4-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine;
I-19: N2-(4-cyclopropyl-2-fluoro-5-(5-(trifluoromethyl)-1H-tetrazol-1-yl)phenyl)-5-fluoro-N4-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine;
I-20: N2-(4-cyclopropyl-2-fluoro-5-(5-(fluoromethyl)-1H-tetrazol-1-yl)phenyl)-5-fluoro-N4-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine; and
I-21: Trans-5-fluoro-N2-(2-fluoro-5-(1H-tetrazol-1-yl)-4-(2-(trifluoromethyl)cyclopropyl)phenyl)-N4-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine;
or a solvate or a pharmaceutically acceptable salt thereof.
17. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
18. A method of inhibiting a protein kinase C (PKC), which method comprises contacting the protein kinase C with a compound of claim 1 .